… (0.48) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… (0.25) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
… $15.75 per share including full exercise of underwriters’ option to purchase 862,500 additional ordinary shares. Gross … oligonucleotide QR-110 for treatment of inherited retinal dystrophy in adults and children with LCA10 ○ Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Presented at …
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… for QR-110 from the FDA. The planned Phase 1/2 open-label trial (PQ-110-001) will include approximately 6 … 6 adults (≥ 18 years) that have LCA 10 due to one or two copies of the p.Cys998X mutation. During the trial, patients … with expertise in genetic retinal disease in the US and Europe. The primary objective will be to assess safety and …
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in